Childhood leukemia

MasterCraft Launches ‘Surf to Save Lives’ Campaign Supporting St. Jude Children’s Research Hospital®

Retrieved on: 
Wednesday, May 10, 2023

VONORE, Tenn., May 10, 2023 (GLOBE NEWSWIRE) -- MasterCraft Boat Company, the world’s best-selling towboat boat brand five years running, today announced a partnership with St. Jude Children’s Research Hospital® and the launch of its ‘Surf to Save Lives’ campaign benefitting St. Jude. The two Tennessee-based organizations have joined forces with the goal of bringing together the boating community to raise awareness and support the work of St. Jude in researching and treating childhood cancer and other catastrophic pediatric diseases.

Key Points: 
  • Saving children.®
    VONORE, Tenn., May 10, 2023 (GLOBE NEWSWIRE) -- MasterCraft Boat Company, the world’s best-selling towboat boat brand five years running, today announced a partnership with St. Jude Children’s Research Hospital® and the launch of its ‘Surf to Save Lives’ campaign benefitting St. Jude.
  • Prominent celebrities and attending guests can join MasterCraft on the water to log their activity time and raise money for St. Jude.
  • In addition to the company’s contribution through the Surf to Save Lives campaign, MasterCraft employees can make a pledge to St. Jude through an Employee Giving Program.
  • For more information about MasterCraft and the Surf to Save Lives campaign please visit https://www.mastercraft.com/stjude .

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Do not breastfeed while receiving RYLAZE and for 1 week after the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.
  • Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Leukemia & Lymphoma.

Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Retrieved on: 
Tuesday, January 4, 2022

One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."

Key Points: 
  • One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."
  • Adoptive immunotherapy, in which a patient's own immune system is used to kill cancer cells, has been a breakthrough in the treatment of B-ALL.
  • Although earlier studies had shown that CD22 undergoes alternative splicing, the role of these CD22 isoforms in the context of immunotherapy had not been characterized.
  • In one case, it was the only CD22 isoform, and predictably that patient did not respond to treatment with inotuzumab.

NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 13, 2021

We have been exploring with collaborators the potential of novel treatments targeting Siglec-15 and LAIR-1 for hematologic indications.

Key Points: 
  • We have been exploring with collaborators the potential of novel treatments targeting Siglec-15 and LAIR-1 for hematologic indications.
  • Data from both studies showcase encouraging signs that our therapeutic approaches could be beneficial for patients with multiple aggressive forms of leukemia.
  • In this study, researchers knocked out S15 in a murine model of both immunocompetent and immunodeficient B-ALL cells.
  • Youshould not place undue reliance on any forward-looking statements.NextCureassumes no obligation to update any forward-looking statements, even if expectations change.

NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021

Details related to the poster presentations are as follows:

Key Points: 
  • Details related to the poster presentations are as follows:
    Session Name: 616.
  • Words such as expects, believes, intends, hope, forward and similar expressions are intended to identify forward-looking statements.
  • Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement.
  • Youshould not place undue reliance on any forward-looking statements.NextCureassumes no obligation to update any forward-looking statements, even if expectations change.

UPDATE - InvestmentPitch Media Video Discusses Pascal Biosciences and its Non-Brokered Private Placement to Raise up to $900,000 with $0.10 Units – Video Available on Investmentpitch.com

Retrieved on: 
Wednesday, November 3, 2021

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.

Key Points: 
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • If this link is not enabled, please visit www.InvestmentPitch.com and enter Pascal in the search box.
  • Pascal already has a corporate partnership with SoRSE Technology for their PAS-393 program, and an NIH grant for their leukemia program.
  • The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

Childhood Cancer Prevention Initiative Ramps up Advocacy during Childhood Cancer Awareness Month as New Data Shows Childhood Cancer Upward Trend Continues

Retrieved on: 
Monday, September 20, 2021

"The trend doesn't look good for childhood cancers in this country.

Key Points: 
  • "The trend doesn't look good for childhood cancers in this country.
  • Many childhood cancers are preventable" said David Levine, Co-founder & President of American Sustainable Business Council and a leading member of the CCPI.
  • The new findings , within just one year of the release of the report, are driving an upsurge of advocacy efforts and commitments to help reduce the risk of childhood cancer.
  • This Childhood Cancer Awareness Month, leaders from various sectors have organized a series of six panel webinars that will take place from September 20th 24th.

Retired Cancer Doctor, Edward Arenson MD CWSP, Chronicles Inspiring 50-Year Career in Compelling New Memoir

Retrieved on: 
Monday, January 25, 2021

In 1971 childhood leukemia was the most feared disease in the era of antibiotics, was the most common cancer of childhood, and was 100% fatal, said Dr. Arenson.

Key Points: 
  • In 1971 childhood leukemia was the most feared disease in the era of antibiotics, was the most common cancer of childhood, and was 100% fatal, said Dr. Arenson.
  • His book provides further details on this major medical development along with numerous other advances Dr. Arenson consulted on during his remarkable career.
  • Lisa Brown-Gilbert for the Pacific Book Review
    Edward Arenson MD CWSP graduated from Cornell University in 1967 and Drexel University Medical College in 1971.
  • This evolved for Dr. Arenson into an interest in adults with brain cancer which became his predominant interest until his retirement in early 2020.

City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference

Retrieved on: 
Tuesday, December 8, 2020

City of Hope doctors are leading novel clinical trials for patients with leukemia, lymphoma and other blood cancers.

Key Points: 
  • City of Hope doctors are leading novel clinical trials for patients with leukemia, lymphoma and other blood cancers.
  • City of Hope and other institutions started this therapy in 1976, primarily for younger patients with blood cancers.
  • Because of these and other considerations, for many years, older adults with blood cancers have not been considered for transplants.
  • City of Hope has been leading the way to make transplants possible for more older adults with various cancers.